Healthineers Wins Higher Targets but Not Upgrades as Diagnostics Drags on the Turnaround

Two of the Street's biggest houses have nudged their price targets on Siemens Healthineers higher in as many days, yet neither was willing to shift its rating. Goldman Sachs lifted its target to €49 from €43 on Monday while keeping a "Neutral" stance, a day after Deutsche Bank Research moved to €43 from €39 and stuck with "Hold." The pattern says as much about the shape of the medical-technology group's turnaround as it does about the analysts themselves: the direction of travel is upward, but conviction is in short supply.

Falko Friedrichs at Deutsche Bank pinned his caution on a mixed set of results and the prospect of another transitional year. The stock added 0.6% in the prior session.

At the heart of the hesitation is the profit outlook. In guidance published about a week ago, Siemens Healthineers projected adjusted earnings per share of €2.20 to €2.40 for fiscal 2026/27, against €2.42 delivered in fiscal 2026. Even the top end of that range sits below what the company has just reported — a detail that carries more weight for investors than revenue growth on its own. Comparable revenue is forecast to expand 4.0% to 5.0% in 2026/27, versus 4.0% in fiscal 2026, when the adjusted EBIT margin came in at 16.2%. Analysts had been looking for 5.5% revenue growth, leaving room for a positive surprise only if the operating trajectory cooperates.

The bull case rests on momentum into the year-end. Comparable revenue climbed 5.9% in the fourth quarter of fiscal 2026, well ahead of the 4.0% pace for the full year. Should that acceleration hold, it would help underwrite earnings through the restructuring. Cost savings announced about a week ago could add further headroom: Reuters reported that Siemens Healthineers is targeting €400 million at Diagnostics and at least €300 million in the core business. Those measures become a credible argument for investors only if they translate into steadier earnings.

Weighing on the other side of the ledger is Diagnostics itself. While group comparable revenue grew in the fourth quarter of fiscal 2026, the diagnostics division contracted 4.2%. A continuation of that trend would complicate the push for earnings stability. The carve-out initiated on 5 November aims to turn the in-vitro diagnostics business into a standalone organization by mid-2028 under the name Olyrian Diagnostics; until then, it remains part of the group. Chief financial officer Jochen Schmitz said the savings program will also affect jobs, according to Reuters.

Alongside the separation, the company said on 5 November that it will shorten its name to "Healthineers," with the rebrand set to begin in 2027 and run over three years.

For holders, the question is whether the higher targets are a down payment on a re-rating or merely a nod to better sentiment. The optimistic path requires revenue growth and cost savings to work in tandem, with the profit landing point inside the range and a convincing account of the earnings trajectory beyond it. The cautious path is a prolonged Diagnostics slump while the savings have yet to bite, weighing on results for longer than bulls expect. Until the operating numbers settle the argument, the raised targets carry limited weight on their own.